Ipamorelin

Overview

Ipamorelin is a synthetic research peptide classified as a selective growth hormone secretagogue (GHS). It is widely studied in laboratory settings for its potential to stimulate the natural release of growth hormone in test models such as laboratory rodents. Ipamorelin is noted for its targeted action with minimal impact on cortisol and prolactin levels compared to other GHS peptides.

Benefits

Preclinical research suggests that Ipamorelin may promote enhanced growth hormone secretion, improved recovery, increased lean tissue growth, and support fat metabolism in research subjects. Its selective mechanism of action makes it a valuable tool for studies exploring growth hormone pathways with fewer unwanted hormonal effects.
Source: Aslanian MG, et al. Ipamorelin, a selective GH secretagogue, mimics the GH-releasing effect of GHRP-6 without stimulating ACTH or cortisol release. Journal of Clinical Endocrinology & Metabolism, 1998. Link

Possible Side Effects

In laboratory environments, test subjects administered Ipamorelin may experience mild side effects including temporary injection site irritation, mild water retention, or slight fluctuations in appetite. Its selective nature typically results in fewer off-target hormonal effects compared to other growth hormone secretagogues.
Source: Aslanian MG, et al., JCEM, 1998. Link

Dosage & Administration

Ipamorelin is administered via subcutaneous injection under approved research protocols. Common research dosages range from 200 mcg to 500 mcg per injection, typically administered once to multiple times daily depending on the study design and species used. Ipamorelin is often combined with a GHRH analog in research to optimize growth hormone release.
For laboratory research use only. Not for human consumption.

Summary

Ipamorelin is a selective growth hormone secretagogue designed exclusively for research exploring safe and targeted growth hormone release in preclinical models. Studies have shown it can support growth hormone stimulation with fewer hormonal side effects, with mild injection site reactions or water retention occasionally observed. Ipamorelin is typically administered by subcutaneous injection daily or multiple times per day, with dosage tailored to research goals and species.
Strictly for research purposes only. Not for human use.